Previous 10 | Next 10 |
Compugen Announces Appointment of Dr. Mathias Hukkelhoven to its Board of Directors PR Newswire HOLON, Israel , Feb. 24, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), ("Compugen", the "Company"), a clinical-stage cancer immunotherapy company and...
Compugen Reports Fourth Quarter and Full Year 2021 Results - Enrollment underway in all dose expansion studies with potential first-in-class anti-PVRIG antibody COM701 and potential best-in-class anti-TIGIT antibody COM902 - First data from combination studies expected in Q4...
Compugen (NASDAQ:CGEN) is scheduled to announce Q4 earnings results on Thursday, February 24th, before market open. The consensus EPS Estimate is -$0.13 (-30.0% Y/Y) and the consensus Revenue Estimate is $0.86M (-57.0% Y/Y). Over the last 3 months, EPS estimates have seen 0 upward revisions a...
Compugen to Release Fourth Quarter and Full Year 2021 Results on Thursday, February 24, 2022 PR Newswire HOLON, Israel , Feb. 10, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predict...
Compugen to Present at the 11th Annual SVB Leerink Global Healthcare Conference PR Newswire HOLON, Israel , Feb. 9, 2022 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today...
Compugen Expands COM701 Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use with anti-PD-1 and anti-TIGIT Antibodies - Broad method of use patent protection for COM701, a potential first-in-class anti-PVRIG antibody, in triple combination with an...
Compugen Presents Preliminary Translational Data Demonstrating Immune Activation in the Tumor Microenvironment by COM701 at the TIGIT Therapies Digital Summit - TIGIT and PVRIG are key parallel and complementary inhibitory pathways in the DNAM-1 axis which intersect with the wel...
Ark Invest, and in particular the Ark Innovation ETF have had an incredible run over the past five years. However, much of these gains came from factors that are no longer applicable to the fund today. The fund's excessive size and concentration in positions are making it difficul...
Cathie Wood’s ARK Invest Funds Are Buying Penny Stocks But Are They Worth It? By simple definition, penny stocks are shares of stock trading for less than $5. Some may define them by exchange, while others place a lower price threshold on these cheap stocks. Needless to say, if y...
Compugen (NASDAQ: CGEN) stock didn't begin this week in a healthy way. The clinical-stage drug company's shares fell by just over 7% following a price target cut from an analyst tracking the company. Prognosticator Mark Breidenbach of Oppenheimer has trimmed said target by j...
News, Short Squeeze, Breakout and More Instantly...
Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors PR Newswire FDA clearance triggers a $30 million milestone payment from Gilead Company on track to initiate a Phase 1 trial for COM503, a differentiated antibody approach to harne...
Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024 PR Newswire HOLON, Israel , July 23, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target ...
Compugen to Present at Upcoming Antibody Industrial Symposium PR Newswire HOLON, Israel , June 17, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, t...